Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Diabetology International
Erschienen in: Diabetology International 1/2016

01.03.2016 | Review Article

Implications of using HBA1C as a diagnostic marker for diabetes

verfasst von: Nadia Hussain

Erschienen in: Diabetology International | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Diagnosing diabetes now includes a new criterion; hemoglobin A1C ≥6.5 % which can have significant implications. This review compares the advantages and disadvantages of using HbA1C as the main diabetic diagnostic test. HbA1C has greater stability and less variability than plasma glucose measurements but may not always reflect glycemic levels of glycaemia. The present cut off value identifies fewer diabetics than glucose-based criteria. HbA1C being more convenient could diagnose more patients but this is not yet proven. When choosing a diagnostic test, the limitations of each test must be clearly understood to use appropriate clinical judgment and consider patient preference.
Literatur
1.
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.CrossRefPubMed
2.
Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed
3.
4.
5.
6.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRefPubMed
7.
Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.CrossRefPubMed
8.
9.
Association AD. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014;37(Supplement 1):S81–90.CrossRef
10.
Association AD. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.CrossRef
11.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.CrossRef
12.
Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia. 2009;52(7):1279–89.CrossRefPubMed
13.
Tapp RJ, Tikellis G, Wong TY, Harper CA, Zimmet PZ, Shaw JE. Longitudinal association of glucose metabolism with retinopathy: results from the Australian diabetes obesity and lifestyle (AusDiab) study. Diabetes Care. 2008;31(7):1349–54.CrossRefPubMedPubMedCentral
14.
Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance results from the veterans administration genetic epidemiology study. Diabetes. 2006;55(5):1430–5.CrossRefPubMed
15.
Allen DW, Schroeder W, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal human hemoglobin: a study of the effects of crystallization and chromatography on the heterogeneity and isoleucine content. J Am Chem Soc. 1958;80(7):1628–34.CrossRef
16.
Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968;22(2):296–8.CrossRefPubMed
17.
Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36(5):838–43.CrossRefPubMed
18.
Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295(8):417–20.CrossRefPubMed
19.
Koenig RJ, Peterson CM, Kilo C, Cerami A, Williamson JR. Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes. 1976;25(3):230–2.CrossRefPubMed
20.
21.
Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1(1):9–17.CrossRefPubMed
22.
Carruthers A. Facilitated diffusion of glucose. Physiol Rev. 1990;70(4):1135–76.PubMed
23.
Lenters-Westra E, Slingerland RJ. Hemoglobin A1c determination in the A1C-Derived Average Glucose (ADAG) study. Clin Chem Lab Med. 2008;46(11):1617–23.CrossRefPubMed
24.
Jeffcoate S. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med. 2004;21(7):657–65.CrossRefPubMed
25.
Borch-Johnsen K, Colagiuri S. Diagnosing diabetes—time for a change? Diabetologia. 2009;52(11):2247–50.CrossRefPubMed
26.
Rohlfing C, Wiedmeyer H-M, Little R, Grotz VL, Tennill A, England J, et al. Biological variation of glycohemoglobin. Clin Chem. 2002;48(7):1116–8.PubMed
27.
Mikesh LM, Bruns DE. Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin Chem. 2008;54(5):930–2.CrossRefPubMed
28.
29.
Tapp RJ, Tikellis G, Wong TY, Harper CA, Zimmet PZ, Shaw JE. Longitudinal association of glucose metabolism with retinopathy results from the Australian diabetes obesity and lifestyle (AusDiab) Study. Diabetes Care. 2008;31(7):1349–54.CrossRefPubMedPubMedCentral
30.
Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34(1):145–50.CrossRefPubMedPubMedCentral
31.
Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Ehlers GW, et al. State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. Arch Pathol Lab Med. 2008;132(5):838–46.PubMed
32.
Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of clinical chemistry and laboratory medicine, and the International Diabetes Federation. Diabetes Care. 2007;30(9):2399.CrossRef
33.
Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–11.CrossRefPubMedPubMedCentral
34.
McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259–64.CrossRefPubMed
35.
Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract. 2010;87(3):415–21.CrossRefPubMed
36.
Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucose-independent, black-white differences in hemoglobin A1c levels a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152(12):770–7.CrossRefPubMed
37.
Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97(4):1067–72.CrossRefPubMedPubMedCentral
38.
Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005;51(4):776–8.CrossRefPubMed
39.
Gambino R. Glucose: a simple molecule that is not simple to quantify. Clin Chem. 2007;53(12):2040–1.CrossRefPubMed
40.
Christensen DL, Witte DR, Kaduka L, Jørgensen ME, Borch-Johnsen K, Mohan V, et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care. 2010;33(3):580–2.CrossRefPubMedPubMedCentral
41.
Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F, et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao,China. Diabetes Care. 2010;33(3):545–50.CrossRefPubMedPubMedCentral
42.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.CrossRefPubMed
43.
Eriksson K-F, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise. Diabetologia. 1998;41(9):1010–6.CrossRefPubMed
44.
Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Ten-year mortality and cardiovascular morbidity in the finnish diabetes prevention study-secondary analysis of the randomized trial. PLoS One. 2009;4(5):e5656.CrossRefPubMedPubMedCentral
45.
Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the US population in 1988–2006. Diabetes Care. 2010;33(3):562–8.CrossRefPubMedPubMedCentral
46.
Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among US adults. Diabetes Care. 2010;33(1):95–7.CrossRefPubMedPubMedCentral
47.
Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C Between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors the insulin resistance atherosclerosis study (IRAS). Diabetes Care. 2010;33(9):2104–9.CrossRefPubMedPubMedCentral
48.
Pajunen P, Peltonen M, Eriksson J, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, et al. HbA1c in diagnosing and predicting type 2 diabetes in impaired glucose tolerance: the finnish diabetes prevention study. Diabet Med. 2011;28(1):36–42.CrossRefPubMed
49.
Committee IE. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–34.CrossRef
50.
Colagiuri S, Borch-Johnsen K. DETECT-2: early detection of type 2 diabetes and IGT. Diabetes Voice. 2003;48(4):11–3.
51.
Borch-Johnsen K, Colagiuri S. Diagnosing diabetes–time for a change? Diabetologia. 2009;52(11):2247–50.CrossRefPubMed
52.
McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308(6940):1323–8.CrossRefPubMedPubMedCentral
53.
Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997;20(5):785–91.CrossRefPubMed
54.
Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin-potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281(13):1203–10.CrossRefPubMed
55.
Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care. 2009;32(11):2027–32.CrossRefPubMedPubMedCentral
56.
Miyazaki M, Kubo M, Kiyohara Y, Okubo K, Nakamura H, Fujisawa K, et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama study. Diabetologia. 2004;47(8):1411–5.CrossRefPubMed
57.
Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736–43.CrossRefPubMedPubMedCentral
58.
van Leiden HA, Moll AC, Dekker JM, Abramoff MD, Polak BC. Photography or ophthalmoscopy for detection of diabetic retinopathy? Diabetes Care. 2003;26(4):1318–9.CrossRefPubMed
59.
Group DPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393.CrossRef
60.
Cohen RM, Smith EP. Frequency of HbA1c discordance in estimating blood glucose control. Curr Opin Clin Nutr Metab Care. 2008;11(4):512–7.CrossRefPubMed
61.
van’t Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care. 2010;33((1)):61–6.CrossRef
62.
Lapolla A, Tubaro M, Fedele D, Reitano R, Arico N, Ragazzi E, et al. A matrix-assisted laser desorption/ionization mass spectrometry study of the non-enzymatic glycation products of human globins in diabetes. Rapid Commun Mass Spectrom. 2005;19(2):162–8.CrossRefPubMed
63.
Lapolla A, Mosca A, Fedele D. The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr Metab Cardiovasc Dis. 2011;21(7):467–75.CrossRefPubMed
64.
65.
Metadaten
Titel
Implications of using HBA1C as a diagnostic marker for diabetes
verfasst von
Nadia Hussain
Publikationsdatum
01.03.2016
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 1/2016
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-015-0244-9

Weitere Artikel der Ausgabe 1/2016

Diabetology International 1/2016 Zur Ausgabe

Original Article

Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance

Original Article

Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus

Original Article

Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level

Case Report

A case of glucocorticoid-induced diabetes in which the efficacy between sitagliptin and metformin was compared

Short Communication

Association between attentional function and postural instability in Japanese older patients with diabetes mellitus

Original Article

Association between symptoms of bilateral numbness and/or paresthesia in the feet and postural instability in Japanese patients with diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise